Continuing Education (CE) Information

International Myeloma Society (IMS)
18th International Myeloma Workshop
Live in Vienna, Austria September 08 - 11, 2021
Enduring Online September 11, 2021 through December 31, 2021

Acknowledgement of Financial Commercial Support 
No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Satisfactory Completion  
Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety.  Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.  

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and International Myeloma Society (IMS).  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME) Credit Designation

Amedco LLC designates this live activity / enduring material for a maximum of 27.75 live / 27.75 enduring AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 27.75 live / 27.75 enduring ANCC contact hours.

Objectives - After Attending This Program You Should Be Able To

  1. Recognize the progress on genomic landscape and evolution of multiple myeloma and the surrounding genetic environment.
  2. Recognize diagnostic and treatment implications with antibody treatment approaches for multiple myeloma.
  3. Utilize recent clinico-pathological and molecular findings to distinguish multiple myeloma from overlapping plasma cell disorders.

Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.  All of these relationships were treated as a conflict of interest, and have been resolved.  (C7 SCS 6.1-­‐6.2, 6.5) 

How to Get Your Certificate

  1. Go to
  2. Click on the “9.8.21 18th International Myeloma Workshop” link.
  3. Evaluate the meeting.
  4. Print all pages of your certificate for your records. 

Questions? Email